Flot.bio hat dies direkt geteilt
New episode: I’m with Adrian (Ad) Rawcliffe of Adaptimmune 🇬🇧, the company behind the first engineered cell therapy for solid tumors that has been approved. — — — Thank you to today’s sponsor, Merck Life Science, who can support your antibody drug discovery. Learn more and claim a cool antibody pin here: https://bit.ly/4e2Ed3J — — — “There are very few cell surface proteins that are completely specific to cancer.” We talked about Tecelra's commercial rollout. “Peak sales, it was a $400M figure for the annual sales and with pretty high gross margin. An analyst from Guggenheim thought it was rather $180M. What do you think?” We also talked about what's next in cell therapy, and Philly Cheesesteak vs Fish and Chips. You can now watch and listen to the full episode for free on YouTube, Spotify or Apple (link in the comments 👇)